Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM) today and set a price target of $3. The company’s shares opened today at $0.68.
McCarthy wrote:
“Actinium held a conference call to discuss the next program for CD-33 targeting antibody Ac-225 Lintuzumab (Actimab); targeting a combination with AbbVie’s (ABBV – NR) venetoclax (Venclexta) in relapsed/refractory acute myeloid leukemia (r/r AML).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 8.2% and a 44.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $4.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 1.04M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
